JP2005503423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503423A5 JP2005503423A5 JP2003530202A JP2003530202A JP2005503423A5 JP 2005503423 A5 JP2005503423 A5 JP 2005503423A5 JP 2003530202 A JP2003530202 A JP 2003530202A JP 2003530202 A JP2003530202 A JP 2003530202A JP 2005503423 A5 JP2005503423 A5 JP 2005503423A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- acid
- group
- carbon atoms
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 33
- 125000004432 carbon atom Chemical group C* 0.000 claims 32
- 150000007524 organic acids Chemical group 0.000 claims 30
- 239000000126 substance Substances 0.000 claims 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 24
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 20
- 230000000561 anti-psychotic effect Effects 0.000 claims 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 239000011593 sulfur Substances 0.000 claims 12
- 230000001028 anti-proliverative effect Effects 0.000 claims 11
- 239000000164 antipsychotic agent Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical group OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 208000020016 psychiatric disease Diseases 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 6
- 150000001263 acyl chlorides Chemical class 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000005022 packaging material Substances 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- -1 amylsulpride residue Chemical group 0.000 claims 5
- 230000003034 chemosensitisation Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical group C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical group C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid group Chemical group C(C=1C(C(=O)O)=CC=CC1)(=O)O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 3
- 229960000607 ziprasidone Drugs 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical group C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical group CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 2
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical group NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 claims 2
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical group C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 claims 2
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical group C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 claims 2
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical group COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 claims 2
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical group C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 claims 2
- 206010061040 Childhood psychosis Diseases 0.000 claims 2
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical group C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 claims 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical group C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 2
- 206010033864 Paranoia Diseases 0.000 claims 2
- 208000027099 Paranoid disease Diseases 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical group C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical group CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical group C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960003914 desipramine Drugs 0.000 claims 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical group C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003640 drug residue Substances 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid group Chemical group C(CCCC(=O)O)(=O)O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical group OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 150000002990 phenothiazines Chemical class 0.000 claims 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical group C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 2
- UGBJGGRINDTHIH-UHFFFAOYSA-N piperidine-4-sulfonic acid Chemical group OS(=O)(=O)C1CCNCC1 UGBJGGRINDTHIH-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 2
- 229960000652 sertindole Drugs 0.000 claims 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical group C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical group C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical group C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- SOEYCMDWHXVTQC-UHFFFAOYSA-N 3-aminopropylphosphonous acid Chemical group NCCCP(O)O SOEYCMDWHXVTQC-UHFFFAOYSA-N 0.000 claims 1
- MQIWYGZSHIXQIU-UHFFFAOYSA-O 3-phosphopropylazanium Chemical compound NCCC[P+](O)=O MQIWYGZSHIXQIU-UHFFFAOYSA-O 0.000 claims 1
- CPPMVRLEUZPDOP-UHFFFAOYSA-N 4-amino-2-(1h-imidazol-2-yl)butanoic acid Chemical group NCCC(C(O)=O)C1=NC=CN1 CPPMVRLEUZPDOP-UHFFFAOYSA-N 0.000 claims 1
- HZRGLMRBARSCHX-UHFFFAOYSA-N 4-amino-3-(1h-imidazol-2-yl)butanoic acid Chemical compound OC(=O)CC(CN)C1=NC=CN1 HZRGLMRBARSCHX-UHFFFAOYSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical group OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960003687 alizapride Drugs 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229960002507 benperidol Drugs 0.000 claims 1
- 229960004037 bromperidol Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- ZTHNRNOOZGJLRR-UHFFFAOYSA-N chembl112203 Chemical group NCCCP(O)=O ZTHNRNOOZGJLRR-UHFFFAOYSA-N 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- 229960003864 clotiapine Drugs 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- 229960000394 droperidol Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002690 fluphenazine Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229950011108 nemonapride Drugs 0.000 claims 1
- 229960000762 perphenazine Drugs 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 229960003634 pimozide Drugs 0.000 claims 1
- 229960004265 piperacetazine Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229950001675 spiperone Drugs 0.000 claims 1
- 238000000859 sublimation Methods 0.000 claims 1
- 230000008022 sublimation Effects 0.000 claims 1
- 229960004940 sulpiride Drugs 0.000 claims 1
- 229960004724 sultopride Drugs 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 claims 1
- 229960004728 thiopropazate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32493601P | 2001-09-27 | 2001-09-27 | |
| PCT/IL2002/000795 WO2003026563A2 (en) | 2001-09-27 | 2002-09-29 | Conjugated anti-psychotic drugs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010008725A Division JP2010090170A (ja) | 2001-09-27 | 2010-01-19 | コンジュゲートされた抗精神病薬およびこれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005503423A JP2005503423A (ja) | 2005-02-03 |
| JP2005503423A5 true JP2005503423A5 (https=) | 2006-01-05 |
| JP4521187B2 JP4521187B2 (ja) | 2010-08-11 |
Family
ID=23265759
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530202A Expired - Fee Related JP4521187B2 (ja) | 2001-09-27 | 2002-09-29 | コンジュゲートされた抗精神病薬およびこれらの使用 |
| JP2010008725A Pending JP2010090170A (ja) | 2001-09-27 | 2010-01-19 | コンジュゲートされた抗精神病薬およびこれらの使用 |
| JP2013184566A Pending JP2014015472A (ja) | 2001-09-27 | 2013-09-06 | コンジュゲートされた抗精神病薬およびこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010008725A Pending JP2010090170A (ja) | 2001-09-27 | 2010-01-19 | コンジュゲートされた抗精神病薬およびこれらの使用 |
| JP2013184566A Pending JP2014015472A (ja) | 2001-09-27 | 2013-09-06 | コンジュゲートされた抗精神病薬およびこれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1429844B1 (https=) |
| JP (3) | JP4521187B2 (https=) |
| KR (4) | KR20100097224A (https=) |
| CN (2) | CN101445494A (https=) |
| AT (1) | ATE541588T1 (https=) |
| CA (1) | CA2461663A1 (https=) |
| ES (2) | ES2399977T3 (https=) |
| IL (2) | IL161083A0 (https=) |
| MX (1) | MXPA04002912A (https=) |
| WO (1) | WO2003026563A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4521187B2 (ja) * | 2001-09-27 | 2010-08-11 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | コンジュゲートされた抗精神病薬およびこれらの使用 |
| US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| EP2272537A3 (en) | 2005-06-07 | 2014-10-22 | Ramot at Tel-Aviv University Ltd. | Salts of conjugated psychotropic drugs and processes of preparing same |
| JP5284779B2 (ja) * | 2005-06-07 | 2013-09-11 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |
| CN101506188B (zh) * | 2006-06-22 | 2014-01-15 | 雷蒙特亚特特拉维夫大学有限公司 | 作为具外周系统限制活性药物的五羟色胺再摄取抑制剂 |
| US9278947B2 (en) | 2006-06-22 | 2016-03-08 | Ramot At Tel-Aviv University Ltd. | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| EP2051735B1 (en) * | 2006-07-17 | 2012-08-29 | Ramot, at Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders |
| EP2101585A4 (en) * | 2006-11-30 | 2011-06-15 | Cenerx Biopharma Inc | PIVAGABIN DIALKYLAMINOAL CYLTERS AS A MEDICAMENT FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| WO2009101616A1 (en) | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| MX2010014203A (es) | 2008-06-20 | 2011-02-22 | Astrazeneca Ab | Derivados de dibenzotiazepina y sus usos - 424. |
| CN105330603A (zh) * | 2008-10-08 | 2016-02-17 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
| WO2011070579A1 (en) * | 2009-12-09 | 2011-06-16 | Biolinerx Ltd. | Methods of improving cognitive functions |
| AU2014202425B2 (en) * | 2009-12-31 | 2015-11-19 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| CN107714703A (zh) * | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| US8377929B2 (en) | 2010-02-24 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same |
| EP3476218A1 (en) | 2010-03-11 | 2019-05-01 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
| CN111329865A (zh) * | 2020-03-30 | 2020-06-26 | 华东理工大学 | 奋乃静在制备治疗子宫内膜癌的药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL227699A (https=) | 1957-09-11 | 1900-01-01 | ||
| US3194733A (en) * | 1961-04-26 | 1965-07-13 | Olin Mathicson Chemical Corp | Phenothiazine compositions and method of treating mental disorders |
| GB1460713A (en) * | 1973-06-08 | 1977-01-06 | Kefalas As | 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine |
| US3947579A (en) | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
| US3978216A (en) * | 1974-06-03 | 1976-08-31 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
| US3956493A (en) * | 1974-10-21 | 1976-05-11 | E. R. Squibb & Sons, Inc. | Long acting tranquilizing agent |
| US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
| US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
| US4138484A (en) | 1976-08-16 | 1979-02-06 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
| GB1540842A (en) * | 1976-08-25 | 1979-02-14 | Kefalas As | Phenothiazines |
| US5525727A (en) * | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| US5104858A (en) * | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
| JPH0672868A (ja) * | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| IL139975A0 (en) | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| CN1375287A (zh) * | 2001-03-16 | 2002-10-23 | 王玉万 | 含氯氰碘柳胺或其钠盐的兽用混悬注射剂 |
| JP4521187B2 (ja) * | 2001-09-27 | 2010-08-11 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | コンジュゲートされた抗精神病薬およびこれらの使用 |
-
2002
- 2002-09-29 JP JP2003530202A patent/JP4521187B2/ja not_active Expired - Fee Related
- 2002-09-29 ES ES10182948T patent/ES2399977T3/es not_active Expired - Lifetime
- 2002-09-29 KR KR1020107016372A patent/KR20100097224A/ko not_active Ceased
- 2002-09-29 CN CNA200810190781XA patent/CN101445494A/zh active Pending
- 2002-09-29 WO PCT/IL2002/000795 patent/WO2003026563A2/en not_active Ceased
- 2002-09-29 AT AT02772790T patent/ATE541588T1/de active
- 2002-09-29 CN CNB028236009A patent/CN100558365C/zh not_active Expired - Fee Related
- 2002-09-29 IL IL16108302A patent/IL161083A0/xx unknown
- 2002-09-29 ES ES02772790T patent/ES2379544T3/es not_active Expired - Lifetime
- 2002-09-29 MX MXPA04002912A patent/MXPA04002912A/es active IP Right Grant
- 2002-09-29 EP EP02772790A patent/EP1429844B1/en not_active Expired - Lifetime
- 2002-09-29 KR KR1020127002565A patent/KR101238452B1/ko not_active Expired - Fee Related
- 2002-09-29 KR KR1020047004581A patent/KR100996239B1/ko not_active Expired - Fee Related
- 2002-09-29 EP EP10182948A patent/EP2275143B1/en not_active Expired - Lifetime
- 2002-09-29 KR KR1020097024590A patent/KR20090130150A/ko not_active Ceased
- 2002-09-29 CA CA002461663A patent/CA2461663A1/en not_active Abandoned
-
2009
- 2009-11-23 IL IL202291A patent/IL202291A0/en unknown
-
2010
- 2010-01-19 JP JP2010008725A patent/JP2010090170A/ja active Pending
-
2013
- 2013-09-06 JP JP2013184566A patent/JP2014015472A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005503423A5 (https=) | ||
| JP2007530529A5 (https=) | ||
| US7939525B2 (en) | Conjugated psychotropic drugs and uses thereof | |
| US9890150B2 (en) | Fatty acid conjugates of quetiapine, process for making and using the same | |
| JP2014015472A (ja) | コンジュゲートされた抗精神病薬およびこれらの使用 | |
| JP2008545777A (ja) | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |